Atrial Natriuretic Peptide (ANP) (C49H84N20O15S), rat: Mechanism, Evidence & Research Applications

Executive Summary: Atrial Natriuretic Peptide (ANP) is a 28-amino acid peptide hormone central to blood pressure and fluid regulation in mammals, synthesized and secreted by atrial myocytes in response to hemodynamic stress (APExBIO product information). ANP acts as a vasodilator and promotes natriuresis and diuresis, reducing circulatory load and supporting sodium and water homeostasis. The research-grade ANP (A1009) from APExBIO is supplied at >95.9% purity, providing consistent results in cardiovascular research (internal application guide). ANP’s mechanism involves cyclic GMP signaling and modulation of renal, vascular, and adipose tissue functions. Proper handling, solubilization, and storage are critical for experimental reproducibility, with best practices outlined below.

Biological Rationale

Atrial Natriuretic Peptide (ANP) was first identified as a cardiac hormone regulating blood volume and pressure. Synthesized in cardiac atrial myocytes, ANP is released in response to atrial stretch, angiotensin II, endothelin, and adrenergic signals. Its primary physiological role is to counteract the renin-angiotensin-aldosterone system (RAAS) by promoting natriuresis (renal sodium excretion), diuresis (urine output), and vasodilation, thereby lowering systemic blood pressure. ANP also influences adipose tissue metabolism and inhibits pathological cardiac remodeling (see comparative review). This biological rationale supports its widespread use as a model peptide in cardiovascular and metabolic research.

Mechanism of Action of Atrial Natriuretic Peptide (ANP) (C49H84N20O15S), rat

ANP exerts its effects primarily by binding to natriuretic peptide receptor-A (NPR-A), a guanylyl cyclase-coupled receptor on renal, vascular, and adipose tissues. Receptor activation increases intracellular cyclic GMP (cGMP), resulting in smooth muscle relaxation (vasodilation), increased glomerular filtration rate, and inhibition of sodium reabsorption in the renal collecting ducts. ANP also inhibits aldosterone and renin secretion, further reducing sodium retention. In adipose tissue, ANP stimulates lipolysis via cGMP-dependent protein kinase activation (mechanistic analysis).

Evidence & Benchmarks

• ANP reduces blood pressure and extracellular fluid volume by enhancing renal sodium excretion in rats (product documentation).
• The A1009 ANP peptide exhibits a purity of 95.92%, confirmed by HPLC and mass spectrometry, ensuring reproducibility for cardiovascular disease research (internal guide).
• ANP is soluble at ≥122.5 mg/mL in DMSO and ≥43.5 mg/mL in water; it is insoluble in ethanol under standard laboratory conditions (specification sheet).
• ANP’s vasodilatory effect is mediated by cGMP-dependent relaxation of vascular smooth muscle (see workflow optimization).
• ANP modulates adipose metabolism, promoting lipolysis and influencing systemic energy balance (mechanism article).
• Long-term storage of ANP peptide is optimal at -20°C as a solid; solutions should be prepared fresh and used promptly (handling protocol).

Applications, Limits & Misconceptions

ANP is central to experimental models investigating blood pressure homeostasis, natriuresis mechanisms, and the interplay between cardiovascular and adipose tissue regulation. Its research applications span:

• Cardiovascular physiology and hypertension modeling
• Renal function and fluid-electrolyte balance studies
• Metabolic syndrome and adipose tissue signaling research
• Pharmacological screening for natriuretic or vasodilatory agents

This article clarifies and extends the mechanistic perspectives presented in Atrial Natriuretic Peptide (ANP), Rat: Novel Insights by providing detailed solubility and reproducibility benchmarks for the A1009 reagent. It also updates the experimental guidance of Research-Grade Vasodilator Peptide Hormone, adding new storage and handling recommendations for maximal stability.

Common Pitfalls or Misconceptions

• ANP is not a direct substitute for brain natriuretic peptide (BNP); their receptor affinities and tissue effects differ.
• Peptide solubility is solvent-dependent: ANP is insoluble in ethanol and should not be reconstituted in alcohol-based buffers.
• Long-term storage in solution is not recommended; degradation and loss of activity occur even at low temperatures.
• ANP’s effects are context-specific; for example, its vasodilation may be blunted in models with severe endothelial dysfunction.
• Extrapolation of rat ANP data to human clinical contexts requires careful validation due to interspecies sequence differences.

Workflow Integration & Parameters

• Reconstitution: Dissolve ANP at ≥122.5 mg/mL in DMSO or ≥43.5 mg/mL in water. Vortex gently to avoid foaming. Do not use ethanol.
• Storage: Store lyophilized ANP at -20°C for stability. Prepare solutions immediately before use; avoid repeated freeze-thaw cycles.
• Cardiovascular modeling: Typical in vivo dosing in rat studies ranges from 0.1–10 μg/kg, administered intravenously or intraperitoneally, but protocol optimization is required for specific endpoints (product info).
• Adipose metabolism assays: Apply ANP to cell cultures at nanomolar concentrations to study cGMP-mediated lipolysis (internal review).
• Blood pressure measurement: Use tail-cuff or telemetry systems to assess acute ANP effects in rodent models.

Conclusion & Outlook

The research-grade Atrial Natriuretic Peptide (ANP) (C49H84N20O15S), rat, available from APExBIO, is a validated cardiovascular research peptide essential for mechanistic and translational studies in blood pressure and metabolic regulation. Its stability, reproducibility, and well-characterized action make it an indispensable tool for advanced natriuresis mechanism studies and hypertension modeling. Ongoing research is refining the application of ANP in metabolic and neuroinflammatory contexts, but interspecies and storage considerations remain critical for data integrity (recent review).